Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MYOS, an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, has recently received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application Serial No. 13/765,340 covering the Company's proprietary methods of manufacturing Fortetropin, the first clinically proven natural myostatin inhibitor.
Subscribe to our email newsletter
Upon issuance, the U.S. Patent entitled, "Process for Producing a Composition Containing Active Follistatin," will provide intellectual property protection for making the key ingredient in MYOS’ core commercial muscle health products and carries a patent term through early 2033.
"This patent allowance is a significant achievement for MYOS. Patent protection is of the upmost importance as we advance our development and commercialization strategy based on Fortetropin, the primary component in our bionutrition supplement products, as well as future biotherapeutic brands we envision," commented Peter Levy, President and Chief Operating Officer of MYOS.
"A critical element to our success is the ability to protect and maintain our proprietary rights in order to achieve the best outcome for revenue generation and shareholder return. The issuance of the Fortetropin manufacturing patent will enable us to rigorously defend the integrity of our intellectual property portfolio."
The USPTO issues a Notice of Allowance after it makes a determination that a claimed invention is novel and nonobvious in light of all known technology in existence, and that a patent should be granted from such an application.
Based on the timing of this Notice of Allowance, MYOS expects the forthcoming Fortetropin patent to be issued by the end of the third quarter of 2014.
Robert Ashton, M.D., Chief Medical Officer of MYOS added, "The issuance of this patent related to our proprietary methodology to manufacture Fortetropin will strengthen our IP portfolio. This key patent highlights the innovation necessary to create MYOS’ novel myostatin inhibitor technology. The combination of the core components and the process needed to formulate Fortetropin are unique and differentiate it from competitive products targeting muscle health."
Mr. Levy concluded, "Upon issuance of the patent, MYOS will be the only company in the bionutrition, biotherapeutics and medical food space with the ability to produce, sell, offer for sale or import our core formulation specifically designed and manufactured using the proprietary methodology covered by our the patent. We believe that, as the sole owner of all Fortetropin-based formulations, MYOS will have a unique competitive advantage as the leader in the field of muscle health."